NICE no for Halaven in new indication

27 November 2017

A lack of clinical evidence proving its effectiveness has led the National Institute for Care and Health Excellence (NICE) to publish draft guidance refusing to recommend Halaven (eribulin) in locally advanced or secondary breast cancer in English patients who have had only one chemotherapy regimen.

The cost-effectiveness watchdog already recommends Halaven, which is marketed by Japanese pharma major Eisai (TYO: 4523), as an option to be provided on the National Health Service for adults with this type of cancer who have already had two chemotherapy regimens.

But the NICE does not presently consider that the treatment provides value for money after a single round of chemotherapy. Patients who come into this category currently are usually offered an anthracycline, a taxane or capecitabine, depending on what they have had already.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK